

ersonal use only

# Investor Presentation

**pharmaxis**

developing breakthrough treatments for fibrosis and inflammation

Investor Presentation | 28 April 2023

Gary Phillips CEO

# Forward looking statement

This document contains forward-looking statements, including statements concerning Pharmaxis' future financial position, plans, and the potential of its products and product candidates, which are based on information and assumptions available to Pharmaxis as of the date of this document. Actual results, performance or achievements could be significantly different from those expressed in, or implied by, these forward-looking statements. All statements, other than statements of historical facts, are forward-looking statements.

These forward-looking statements are not guarantees or predictions of future results, levels of performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results to differ materially from those expressed in the statements contained in this document. For example, despite our efforts there is no certainty that we will be successful in developing or partnering any of the products in our pipeline on commercially acceptable terms, in a timely fashion or at all. Except as required by law we undertake no obligation to update these forward-looking statements as a result of new information, future events or otherwise.

## March 2023 Quarter Update

- **Encouraging feedback from FDA on PXS-5505 myelofibrosis clinical development**
  - 21 out of 24 patients recruited
  - Interim data from Q4 2022 showed well tolerated drug with encouraging signs of clinical efficacy in patients unsuitable for JAK inhibitors; further major data update due Q2 2023.
  - FDA engaged in type C meeting; existing data justifies plan for immediate move to next phase of clinical development; PXS-5505 plus JAK inhibitor in stable myelofibrosis patients.
  - FPFV in JAK inhibitor combination study expected in 2H 2023; fast start facilitated by use of existing study infrastructure.
- **Last patient dosed in skin scarring drug PXS-6302 in phase 1c study**
  - Last of 50 patients in placebo controlled study with established scars received final dose in March 2023
  - Top line results featuring scar structure and appearance due Q2 2023.
  - Developing protocols for follow up studies in other scar related indications

## Five trials to deliver near term value

Pipeline creates multiple opportunities in high value markets

	Indication	Addressable market (US\$)	Trial design	# patients	Status	Data
PXS-5505	Myelofibrosis (MF)	\$1 billion	Phase 2 open label 6 month study in JAK intolerant / ineligible myelofibrosis patients	24	Recruiting	Interim data released Significant data update mid 2023
			Phase 2 open label 6 month study in JAK intolerant / ineligible myelofibrosis patients	TBD	First Patient 2H 2023	TBD
PXS-6302	Modification of established scars	\$3.5 billion	Phase 1c 3 month placebo controlled study in patients with established scars (>1 year old)	50	Fully Recruited	H1 2023
	Scar prevention	\$3.5 billion	Phase 1c 3 month placebo controlled study in patients with scarring subsequent to a burns injury	50	First patient 2023	2024
PXS-4728	Isolated REM sleep behaviours disorder (iRDB) and neuro inflammation	\$3.5 billion	Phase 2 double blind, placebo controlled study in patients with iRBD	40	First patient mid-year 2023	H1 2025

Personal use only

# News flow

News flow

*Strong and growing pipeline with advancement in studies expected to provide value inflection points in 2023*



## Q1 2023

- Pharmaxis strengthens Board with two new appointments
- PXS-5505 publication by KOL in haematological cancer myelodysplastic syndrome



## Q2 2023

- PXS-5505: Encouraging FDA feedback on plans to progress to JAK inhibitor combination study
- PXS-5505 myelofibrosis monotherapy study: significant data update
- PXS-5505 phase 2a myelofibrosis monotherapy study – fully recruited
- LOX topical drug PXS-6302 top line data from established scars study
- LOX topical drug PXS-6302 commences independent investigator patient studies – scar prevention
- PXS-4728 iRBD / neuro inflammation study commences recruitment



## H2 2023

- PXS-5505 phase 2a myelofibrosis study completed and reports safety and efficacy data
- PXS-5505 phase 2 myelofibrosis study add on to JAK inhibitor commences recruitment



ersonal use only

Personal use only



# pharmaxis

developing breakthrough treatments for fibrosis and inflammation

Pharmaxis Ltd ABN 75 082 811 630

[www.pharmaxis.com.au](http://www.pharmaxis.com.au)



## Contacts

Gary Phillips  
Chief Executive Officer  
[gary.phillips@pharmaxis.com.au](mailto:gary.phillips@pharmaxis.com.au)

David McGarvey  
Chief Financial Officer  
[david.mcgarvey@pharmaxis.com.au](mailto:david.mcgarvey@pharmaxis.com.au)